Search research articles
Contact Us
Filters
Showing results (101-110 of 170) with videos related to
Page
of 17
Sort By:
Journal of Neuro-Oncology
|
July 22, 2020
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition
Isabel Jiménez, Júlia Carabia, Sabela Bobillo, et al.
Cancers
|
February 25, 2022
Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma
Grégoire Quinet, Wendy Xolalpa, Diana Reyes-Garau, et al.
Nature Medicine
|
January 25, 2012
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut, Alba Dalmases, Beatriz Bellosillo, et al.
Annals of Hematology
|
January 7, 2021
Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
Francesc Bosch, Blanca Navarro, Marta Crespo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2008
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication
Francesc Bosch, Ana Ferrer, Neus Villamor, et al.
The Lancet. Haematology
|
June 2, 2024
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study
Olga Salamero, Antonieta Molero, José Antonio Pérez-Simón, et al.
Biomarker Research
|
May 21, 2021
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
Isabel Jiménez, Bárbara Tazón-Vega, Pau Abrisqueta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2009
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia
Francesc Bosch, Pau Abrisqueta, Neus Villamor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Martin Hutchings, Anna Sureda, Francesc Bosch, et al.
Haematologica
|
July 11, 2024
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes
Ángel Serna, Víctor Navarro, Gloria Iacoboni, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 170) with videos related to
Sort By:
Page
of 17
Journal of Neuro-Oncology
|
July 22, 2020
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition
Isabel Jiménez, Júlia Carabia, Sabela Bobillo, et al.
Cancers
|
February 25, 2022
Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma
Grégoire Quinet, Wendy Xolalpa, Diana Reyes-Garau, et al.
Nature Medicine
|
January 25, 2012
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut, Alba Dalmases, Beatriz Bellosillo, et al.
Annals of Hematology
|
January 7, 2021
Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
Francesc Bosch, Blanca Navarro, Marta Crespo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2008
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication
Francesc Bosch, Ana Ferrer, Neus Villamor, et al.
The Lancet. Haematology
|
June 2, 2024
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study
Olga Salamero, Antonieta Molero, José Antonio Pérez-Simón, et al.
Biomarker Research
|
May 21, 2021
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
Isabel Jiménez, Bárbara Tazón-Vega, Pau Abrisqueta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2009
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia
Francesc Bosch, Pau Abrisqueta, Neus Villamor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Martin Hutchings, Anna Sureda, Francesc Bosch, et al.
Haematologica
|
July 11, 2024
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes
Ángel Serna, Víctor Navarro, Gloria Iacoboni, et al.
Page
of 17